<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079880</url>
  </required_header>
  <id_info>
    <org_study_id>HTHEC-2017-09</org_study_id>
    <nct_id>NCT05079880</nct_id>
  </id_info>
  <brief_title>Effect of Caffeine on Time to Anesthetic Emergence After Laparoscopic Cholecystectomy : Randomized-controlled Trial</brief_title>
  <official_title>Effect of Caffeine on Time to Anesthetic Emergence After Laparoscopic Cholecystectomy : Randomized-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tunis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tunis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A faster emergence from general anesthesia has a double medico-economic impact by reducing&#xD;
      the risks of complications and optimizing the performance of surgical units. No drug has been&#xD;
      retained for its ability to actively accelerate anesthetic emergence by antagonizing&#xD;
      hypnotics. Thus, the aim of this study was to examine the effect of caffeine on the time to&#xD;
      emerge from sevoflurane anesthesia for laparoscopic cholecystectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anesthetic recovery time</measure>
    <time_frame>Postoperative</time_frame>
    <description>time to return to spontaneous breathing, eye opening on verbal command and time for extubation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma caffeine levels at H1 and H24</measure>
    <time_frame>Hour 1 and Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative rehabilitation</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>incidence of headache, nausea and vomiting, tiredness score, time to the first flatus and satisfaction of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain (Visual Analog Scale score 0 &quot;no pain&quot; to 10 &quot;severe pain&quot;) and consumption of morphine</measure>
    <time_frame>24 hours postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Laparoscopic Cholecystectomy</condition>
  <arm_group>
    <arm_group_label>GC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received 300 mg of caffeine citrate infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equivalent saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg of caffeine citrate infusion</intervention_name>
    <description>At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period</description>
    <arm_group_label>GC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period</description>
    <arm_group_label>GS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American society of Anesthesiologists (ASA) I and II patients, aged older than 18&#xD;
             years old and scheduled for laparoscopic cholecystectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with an allergy to caffeine citrate and analgesics used during postoperative&#xD;
             period, those with severe renal or hepatic failure, those who refused to participate&#xD;
             in addition to patient with heart rhythm disorder, seizure disorder, hypertension,&#xD;
             alcoholic or psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Aziz DAGHMOURI, M.D</last_name>
    <phone>0021629442474</phone>
    <email>aziz.daghmouri@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Habib Thameur Hospital</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Aziz Daghmouri</last_name>
      <email>aziz.daghmouri@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tunis University</investigator_affiliation>
    <investigator_full_name>Daghmouri Mohamed Aziz</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Caffeine</keyword>
  <keyword>Anesthesia emergence</keyword>
  <keyword>Cholecystectomy</keyword>
  <keyword>Sevoflurane</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Caffeine citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

